Treatment of keratoacanthomas with intralesional methotrexate

J. L. Melton, B. R. Nelson, D. B. Stough, M. D. Brown, Neil Swanson, T. M. Johnson

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Multiple modalities exist for the treatment of keratoacanthoma. Excisional surgery is currently the treatment of choice for the majority of keratoacanthomas. This can result in functional and cosmetic defects when large or strategically located lesions are treated. An effective nonsurgical treatment would be desirable in such cases. Intralesional therapy, particularly with 5-fluorouracil, has been shown to be effective in the treatment of keratoacanthomas. Systemic methotrexate has been tried, with variable success. We report an open, noncontrolled study of nine consecutive patients with unusually large or strategically located solitary keratoacanthomas treated successfully with intralesional methotrexate. All lesions responded promptly, with complete resolution after a mean of 3.0 weeks and a mean of 1.7 injections. No side effects occurred, and scarring was minimal. We concluded that intralesional methotrexate is a simple and effective modality for the treatment of select keratoacanthomas and may offer greater efficacy, a more rapid response, decreased pain, and lower cost compared with intralesional 5-fluorouracil.

Original languageEnglish (US)
Pages (from-to)1017-1023
Number of pages7
JournalJournal of the American Academy of Dermatology
Volume25
Issue number6 I
StatePublished - 1991

Fingerprint

Keratoacanthoma
Methotrexate
Fluorouracil
Therapeutics
Cosmetics
Cicatrix
Costs and Cost Analysis
Pain
Injections

ASJC Scopus subject areas

  • Dermatology

Cite this

Melton, J. L., Nelson, B. R., Stough, D. B., Brown, M. D., Swanson, N., & Johnson, T. M. (1991). Treatment of keratoacanthomas with intralesional methotrexate. Journal of the American Academy of Dermatology, 25(6 I), 1017-1023.

Treatment of keratoacanthomas with intralesional methotrexate. / Melton, J. L.; Nelson, B. R.; Stough, D. B.; Brown, M. D.; Swanson, Neil; Johnson, T. M.

In: Journal of the American Academy of Dermatology, Vol. 25, No. 6 I, 1991, p. 1017-1023.

Research output: Contribution to journalArticle

Melton, JL, Nelson, BR, Stough, DB, Brown, MD, Swanson, N & Johnson, TM 1991, 'Treatment of keratoacanthomas with intralesional methotrexate', Journal of the American Academy of Dermatology, vol. 25, no. 6 I, pp. 1017-1023.
Melton JL, Nelson BR, Stough DB, Brown MD, Swanson N, Johnson TM. Treatment of keratoacanthomas with intralesional methotrexate. Journal of the American Academy of Dermatology. 1991;25(6 I):1017-1023.
Melton, J. L. ; Nelson, B. R. ; Stough, D. B. ; Brown, M. D. ; Swanson, Neil ; Johnson, T. M. / Treatment of keratoacanthomas with intralesional methotrexate. In: Journal of the American Academy of Dermatology. 1991 ; Vol. 25, No. 6 I. pp. 1017-1023.
@article{4119c39871f74bbfbde4611097bf8b6f,
title = "Treatment of keratoacanthomas with intralesional methotrexate",
abstract = "Multiple modalities exist for the treatment of keratoacanthoma. Excisional surgery is currently the treatment of choice for the majority of keratoacanthomas. This can result in functional and cosmetic defects when large or strategically located lesions are treated. An effective nonsurgical treatment would be desirable in such cases. Intralesional therapy, particularly with 5-fluorouracil, has been shown to be effective in the treatment of keratoacanthomas. Systemic methotrexate has been tried, with variable success. We report an open, noncontrolled study of nine consecutive patients with unusually large or strategically located solitary keratoacanthomas treated successfully with intralesional methotrexate. All lesions responded promptly, with complete resolution after a mean of 3.0 weeks and a mean of 1.7 injections. No side effects occurred, and scarring was minimal. We concluded that intralesional methotrexate is a simple and effective modality for the treatment of select keratoacanthomas and may offer greater efficacy, a more rapid response, decreased pain, and lower cost compared with intralesional 5-fluorouracil.",
author = "Melton, {J. L.} and Nelson, {B. R.} and Stough, {D. B.} and Brown, {M. D.} and Neil Swanson and Johnson, {T. M.}",
year = "1991",
language = "English (US)",
volume = "25",
pages = "1017--1023",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "6 I",

}

TY - JOUR

T1 - Treatment of keratoacanthomas with intralesional methotrexate

AU - Melton, J. L.

AU - Nelson, B. R.

AU - Stough, D. B.

AU - Brown, M. D.

AU - Swanson, Neil

AU - Johnson, T. M.

PY - 1991

Y1 - 1991

N2 - Multiple modalities exist for the treatment of keratoacanthoma. Excisional surgery is currently the treatment of choice for the majority of keratoacanthomas. This can result in functional and cosmetic defects when large or strategically located lesions are treated. An effective nonsurgical treatment would be desirable in such cases. Intralesional therapy, particularly with 5-fluorouracil, has been shown to be effective in the treatment of keratoacanthomas. Systemic methotrexate has been tried, with variable success. We report an open, noncontrolled study of nine consecutive patients with unusually large or strategically located solitary keratoacanthomas treated successfully with intralesional methotrexate. All lesions responded promptly, with complete resolution after a mean of 3.0 weeks and a mean of 1.7 injections. No side effects occurred, and scarring was minimal. We concluded that intralesional methotrexate is a simple and effective modality for the treatment of select keratoacanthomas and may offer greater efficacy, a more rapid response, decreased pain, and lower cost compared with intralesional 5-fluorouracil.

AB - Multiple modalities exist for the treatment of keratoacanthoma. Excisional surgery is currently the treatment of choice for the majority of keratoacanthomas. This can result in functional and cosmetic defects when large or strategically located lesions are treated. An effective nonsurgical treatment would be desirable in such cases. Intralesional therapy, particularly with 5-fluorouracil, has been shown to be effective in the treatment of keratoacanthomas. Systemic methotrexate has been tried, with variable success. We report an open, noncontrolled study of nine consecutive patients with unusually large or strategically located solitary keratoacanthomas treated successfully with intralesional methotrexate. All lesions responded promptly, with complete resolution after a mean of 3.0 weeks and a mean of 1.7 injections. No side effects occurred, and scarring was minimal. We concluded that intralesional methotrexate is a simple and effective modality for the treatment of select keratoacanthomas and may offer greater efficacy, a more rapid response, decreased pain, and lower cost compared with intralesional 5-fluorouracil.

UR - http://www.scopus.com/inward/record.url?scp=0025787838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025787838&partnerID=8YFLogxK

M3 - Article

C2 - 1810980

AN - SCOPUS:0025787838

VL - 25

SP - 1017

EP - 1023

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 6 I

ER -